Observational study finds first-line biologic therapy significantly affects ulcerative colitis outcomes, suggesting optimal treatment selection is crucial.
The choice of first-line biologic is highly impacting UC outcome and cannot be fully compensated by later treatments, advocating for the use of the most effective therapeutic option as first-line biologic.
No takes yet. Share an insight, caveat, or question.
M’Baye et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: